Chris Hayes: ‘A devastating blow': Trump guts funding for U.S.'s largest health study of women
This is an adapted excerpt from the April 23 episode of 'All In with Chris Hayes.'
As Donald Trump and Elon Musk continue to gut all kinds of key federal programs, we are once again asking: Who voted for this? This week's example: the Women's Health Initiative.
The National Institutes of Health began the initiative back in 1991. The project started under the leadership of Bernadine Healy, a practicing cardiologist and legendary figure in public health. She was appointed by then-President George H.W. Bush to be the first woman to run the NIH. Healy called the initiative — the largest women's health prevention study in the U.S. — a 'moon walk' for women.
The purpose of the long-term project was to research cancer, heart disease and osteoporosis in postmenopausal women, a group that had been historically neglected by disease prevention researchers.
The initiative is possibly best known for its study of the potential risks of estrogen-plus-progestin hormone therapy to treat the symptoms of menopause. The Women's Health Initiative estimates that research prevented 126,000 cases of breast cancer and 76,000 cases of heart disease over the following decade. Which, in turn, saved more than $35 billion in direct medical costs.
The initiative produces important research to this day. For example, just last May, it released a study finding that calcium-plus-vitamin D supplements do not prevent bone fractures in menopausal women.
But this week, the Women's Health Initiative announced that the Trump administration is cutting its funding. Its regional research centers will close in September. The main research center's future also remains uncertain after January of next year. The funding, in totality, amounts to a mere $10 million annually. (And $10 million is less than half of what U.S. taxpayers have reportedly spent for Trump's golf trips in these first three months of his term.)
JoAnn Manson, a doctor with Harvard Medical School, told Science that the cuts are a 'devastating blow to the health of all older adults in the U.S. and throughout the world.' She added, 'No study is a better example of the enormous scientific impact of research on the prevention of chronic disease in the population.' Chronic disease prevention — that is the point of this research. It's not a partisan issue.
So, the question still stands: Who voted for this? Because I sure don't remember Trump's campaign promise to cut breast cancer research and to make menopause harder for American women.
This article was originally published on MSNBC.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
No drug price pledges in talks with US government, Pfizer CEO says
STORY: Pfizer CEO Albert Bourla said Monday that he and other drug companies met with the Trump administration to discuss lowering U.S. drug prices but no commitments have been made. He made the comments at a Goldman Sachs healthcare conference. Last month President Trump issued an executive order directing drugmakers to lower the prices of their medicines to align with what other countries pay. According to the order, the administration was to set "Most Favored Nation" price targets within 30 days. The Department of Health and Human Services has said it expects drugmakers in the U.S. to set prices for their products at the lowest price paid by other high-income countries. Bourla said he didn't know what the companies would hear in 30 days and added the meetings with the administration so far were cordial but (quote) "not digging into the substance." It is unclear what mechanism the U.S. government will use to lower drug prices - analysts and legal experts have said the policy will be difficult to implement. Bourla said he is hopeful that, given U.S. pressure on European countries to pay more, prices there could increase. He said that if the U.S. resorts to price controls, Pfizer could consider not making drugs available for government reimbursement in some countries if prices don't increase there. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
40 minutes ago
- Yahoo
In letter, more than 300 scientists rebuke Trump research cuts, NIH director
June 9 (UPI) -- Hundreds of scientists via the National Institute of Health signed a published letter in protest to NIH leadership and recent cuts by the Trump administration. "We are compelled to speak up when our leadership prioritizes political moment over human safety and faithful stewardship of public resources," more than 300 scientists wrote Monday to NIH Director Jay Bhattacharya in a so-called "Bethesda Declaration" published by Stand Up For Science in rebuke to Trump administration research funding cuts and staff layoffs. They added in the letter to U.S. Health and Human Services Secretary Robert F. Kennedy Jr. and members of Congress overseeing NIH that they "dissent" to Trump's policies that "undermine" the NIH mission, "waste" public resources and harm "the health of Americans and people across the globe." In the open letter, they said the current endeavor to "Make America Healthy Again" referred to "some undefined time in the past." "Keeping NIH at the forefront of biomedical research requires our stalwart commitment to continuous improvement," the letter's writers said, adding that the life-and-death nature of NIH work "demands that changes be thoughtful and vetted." According to the letter, the Trump administration terminated at least 2,100 NIH research grants since January, totaling around $9.5 billion and contracts representing some $2.6 billion in new research. "We urge you as NIH Director to restore grants delayed or terminated for political reasons so that life-saving science can continue," the letter added in part. "This undercuts long-standing NIH policies designed to maximize return on investment by working with grantees to address concerns and complete studies," it said. It further accused the White House of creating a "culture of fear and suppression" among NIH researchers. Bhattacharya, a Stanford University professor and health researcher, called the agency the "crown jewel of American biomedical sciences" and said he had the "utmost respect" for its scientists and mission during his confirmation hearing in March. On Tuesday, Bhattacharya is scheduled to testify before the Senate's Appropriations Committee on Trump's 2026 NIH budget proposal which seeks to cut roughly 40% of NIH's $48 billion budget. "This spending slowdown reflects a failure of your legal duty to use congressionally-appropriated funds for critical NIH research," the scientists penned to Bhattacharya. The letter goes on to characterize it as "dissent" from Trump administration policy, quoting Bhattacharya during his confirmation as saying "dissent is the very essence of science." "Standing up in this way is a risk, but I am much more worried about the risks of not speaking up," says Jenna Norton, a program officer at the NIH's National Institute of Diabetes and Digestive and Kidney Diseases. "If we don't speak up, we allow continued harm to research participants and public health in America and across the globe," Norton said in a statement, adding that if others don't speak up, "we allow our government to curtail free speech, a fundamental American value."
Yahoo
an hour ago
- Yahoo
ZimVie Stock Gains Following the Launch of RealGUIDE Software Suite
ZimVie Inc. ZIMV recently launched its RealGUIDE Software Suite and Implant Concierge service in Japan. The RealGUIDE platform enables streamlined workflows and enhanced treatment accuracy, while the Implant Concierge service offers personalized support to clinicians throughout the implant process. Together, these solutions aim to boost clinical efficiency and improve patient outcomes in Japan's rapidly evolving dental landscape. As ZimVie's largest market in the Asia-Pacific region, Japan represents a key growth opportunity. The launch is expected to enhance clinician access to end-to-end, vertically integrated digital workflows, reinforcing ZimVie's strategic focus on innovation and global market penetration. Following the announcement, shares of the company have gained 2.9% and closed at $9.38 on Friday. However, in the year-to-date period, ZIMV's shares have lost 32.7% against the industry's 5.9% growth. The S&P 500 increased 1.5% in the same time frame. The launch of the RealGUIDE Software Suite and Implant Concierge service in Japan positions ZimVie to capture a larger share of a high-potential market by offering advanced digital solutions that align with the global shift toward precision-driven, technology-enabled dentistry. By streamlining workflows and enhancing clinician efficiency, these tools can drive increased adoption of ZimVie implants and related products, fostering customer loyalty and recurring revenue. Over time, this strategic move could strengthen ZimVie's footprint in the APAC region, support margin expansion through high-value services, and contribute to sustainable long-term growth. Meanwhile, ZIMV currently has a market capitalization of $261.2 million. Image Source: Zacks Investment Research ZimVie's launch of the RealGUIDE Software Suite in Japan marks a major advancement in digital implantology, offering dentists a robust, cloud-based platform for precise implant planning, surgical guide design and restorative workflows. As the first fully cloud-integrated system of its kind, RealGUIDE allows clinicians to customize their digital workflows using modular components tailored to diagnostic, surgical, and restorative needs. The integration with ZimVie's Dental Technology Institute and its CAD/CAM milling capabilities ensures a seamless transition from case planning to final restoration, significantly improving treatment accuracy, reducing turnaround times, and enhancing patient care. This end-to-end digital experience is poised to streamline operations for clinics while improving efficiency, precision and cost-effectiveness. Complementing the RealGUIDE platform is the Implant Concierge service, a scalable virtual outsourcing solution that supports clinicians in planning and executing guided surgeries with minimal complexity. Designed for user-friendliness and zero upfront investment, Implant Concierge brings together a team of expert treatment planners and designers to ensure accuracy at every step. It integrates directly with dental labs to offer a smooth, fully coordinated experience from planning to final placement, especially beneficial for high-volume practices. Per a report by MarketsandMarkets, the global digital dentistry market, valued at $6.5 billion in 2022, is forecasted to grow at a robust CAGR of 10.9%, reaching $12.2 billion by 2028. The digital dentistry market is rising due to the growing demand for faster, more accurate, and patient-friendly dental procedures. Advancements in 3D imaging, CAD/CAM systems, and cloud-based software are enabling dentists to deliver personalized treatments with greater precision and efficiency. ZIMV carries a Zacks Rank #3 (Hold) at present. Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation CVS, Integer Holdings Corporation ITGR and AngioDynamics ANGO. CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. CVS Health has a long-term estimated growth rate of 11.4%. Its earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%. Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank of 1. Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. AngioDynamics, currently sporting a Zacks Rank #1, reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%. ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 Composite's 10.5% growth. AngioDynamics' earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 70.9%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report ZimVie Inc. (ZIMV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
